Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Status:
Withdrawn
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate tolerability, safety, pharmacokinetics (PK) and
efficacy of oral OKN-007 in participants with recurrent high-grade glioma.